Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

Recombinant Interferon Alfa

3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.

DRUG

Cisplatin

30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.

DRUG

Fluorouracil

175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.

RADIATION

Radiation Therapy

External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.

Trial Locations (1)

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Schering-Plough

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00068575 - Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer | Biotech Hunter | Biotech Hunter